# CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct05257590/  
OnCo record `nct05257590` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nivolumab in hepatocellular carcinoma and metastatic cancer, run by TaiRx, Inc., now recruiting.

## Summary

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT05257590 by TaiRx, Inc., with 95 participants planned, started 2022-05-23 and due to reach its primary completion in 2026-12-31. Interventions recorded: Nivolumab Injection [Opdivo], CVM-1118. Conditions listed: Hepatocellular Carcinoma, Advanced Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05257590
- Phase: 2
- Setting: A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma
- Sponsor: TaiRx, Inc.
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT05257590: https://clinicaltrials.gov/study/NCT05257590

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05257590.json